医学
杜拉鲁肽
体质指数
糖化血红素
2型糖尿病
糖尿病
肥胖
入射(几何)
低血糖
内科学
艾塞那肽
内分泌学
物理
光学
作者
Yongquan Shi,Siying Liu,Jiankun Zhu,Tianpei Hong
标识
DOI:10.1111/1753-0407.13147
摘要
Highlights In Chinese patients with type 2 diabetes (T2D) and body mass index (BMI) <25 kg/m2 , dulaglutide demonstrated great improvements in glycemic control with mild body weight reduction and low hypoglycemia risk. The results indicate that dulaglutide is effective and safe in patients with T2D and lower BMI; therefore, BMI should not be a consideration when dulaglutide is prescribed to Chinese patients with T2D.
科研通智能强力驱动
Strongly Powered by AbleSci AI